Many meta-analyses have focused on advanced or metastasized breast cancer, so we performed a subgroup analysis of HER2+ advanced breast cancer with the T-DM1, LC, HC, NST, PEHC regimens (S9 Table). This evidence concerns the gene ERBB2 and breast carcinoma.